Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Nov;100(5):402-405.
doi: 10.1016/j.contraception.2019.07.144. Epub 2019 Jul 30.

Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi

Yasaman Zia  1 , Jennifer H Tang  2 , Lameck Chinula  3 , Gerald Tegha  3 , Frank Z Stanczyk  4 , Athena P Kourtis  5
Affiliations
Randomized Controlled Trial

Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi

Yasaman Zia et al. Contraception. 2019 Nov.

Abstract

Objective: To compare medroxyprogesterone acetate (MPA) concentrations between HIV-positive women on antiretroviral therapy (ART) and HIV-negative women initiating depot medroxyprogesterone (DMPA) injectable.

Study design: Secondary analysis of 28 HIV-positive women on non-nucleoside reverse transcriptase inhibitor-containing ART regimens and 10 HIV-negative women randomized to initiate DMPA in a clinical trial of progestin contraception in Malawi.

Results: MPA concentrations were significantly lower among HIV-positive women on ART, compared with HIV-negative women, at week 4 and week 13 (p=.03 for both), but not at day 3 or week 26 post-DMPA initiation.

Conclusions: Antiretroviral medications may affect MPA metabolism in HIV-positive African women.

Trial registration: ClinicalTrials.gov NCT02103660.

Keywords: Africa; Antiretroviral therapy; Depot medroxyprogesterone acetate; HIV.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Individual MPA Levels (pg/mL) by Visit for HIV-positive Women (n=28) and HIV-negative Women (n=10). *MPA, medroxyprogesterone acetate.
Fig. 2.
Fig. 2.
MPA Levels (pg/mL) by Visit for Women with MPA<200 At Any Time*MPA, Medroxyprogesterone acetate. **Note: The level of quantification for MPA was 70 pg/mL, and all MPA results below the level of quantification were converted to 35 pg/mL.
See this image and copyright information in PMC

References

    1. United Nations Department of Social and Economic Affairs, Population Division. World Contraceptive Use. 2015.
    1. Medical eligibility criteria for contraceptive use. World Health Organization; 2015. - PubMed
    1. Nanda K, Callahan R, Taylor D, Wang M, Agot K, Jenkins D, et al. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial. Contraception 2016. July 01;94(1):40–7. - PMC - PubMed
    1. Nanda K, Stuart GS, Robinson J, Gray AL, Tepper NK, Gaffield ME. Drug interactions between hormonal contraceptives and antiretrovirals. AIDS 2017. April 24;31(7):917–52. - PMC - PubMed
    1. Kourtis AP, Haddad L, Tang J, Chinula L, Hurst S, Wiener J, et al. A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and negative women in Lilongwe, Malawi: addressing evolving research priorities. Contemp Clin Trials 2017. January 01;52:27–34. - PMC - PubMed

Publication types

Associated data